)
CytomX Therapeutics (CTMX) investor relations material
CytomX Therapeutics Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Platform and partnerships
PROBODY protease-cleavable masks localize potent biologic activity to tumor tissue; platform spans oncology modalities, with potential longer-term applications beyond oncology.
Lead clinical programs are Varseta-M, an EpCAM ADC for late-line colorectal cancer, and masked interferon alpha-2b for post-checkpoint inhibitor melanoma.
Regeneron alliance expanded midyear, with a new milestone announced the night before the conference; partnering advances candidates and generates capital.
Varseta-M efficacy and safety
In fourth-line-or-later CRC, ORR was 20%-30% at 8.6 and 10 mg/kg Q3W; available late-line options have response rates of 1%-2%.
PFS was 6-7 months in patients previously treated with irinotecan, supporting activity of the Topo1 ADC in the post-irinotecan setting.
No pancreatic signal or pancreatic enzyme modulation observed; hematologic toxicity rates were low for a Topo1 ADC.
Grade 3 diarrhea was ~30% at higher doses; upfront loperamide and budesonide reduced it to 10% after two months versus 29% in time-matched earlier cohorts; target is below 20%.
Optimization cohorts mandate both prophylactic drugs and use adjusted ideal body weight dosing to limit overexposure, particularly in patients with high BMI.
Data update and pivotal plans
Phase I enrollment totals 113 patients: 73 in escalation/expansion and 40 in optimization, split between 8.6 and 10 mg/kg Q3W cohorts.
January update planned across the study: longer follow-up, PFS and first OS data for the initial 73 patients, plus ORR and PFS for each 20-patient optimization cohort.
A randomized study of several hundred patients is anticipated, with upfront prophylaxis and OS as the primary endpoint; pivotal launch targeted for H1 next year.
Pivotal options are fourth-line-or-later versus physician's choice regorafenib or fruquintinib, or third-line versus bevacizumab plus LONSURF; January data and FDA feedback will inform the plan.
Fourth-line market potential estimated at $1 billion; total phase I efficacy and exposure-safety data will guide trial design and dose selection.
- Varseta-M shows late-line CRC activity; OS and pivotal-path data are expected Jan 2027.CTMX
3rd Annual Guggenheim Healthcare Innovation Conference - Fast Track Varseta-M advances toward mCRC registration, backed by runway into H2 2028.CTMX
Q3 2026 - Varseta-M’s late-line CRC signal is guiding pivotal planning and expansion.CTMX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Varseta-M advances toward registration as CRC combinations and broader tumor programs progress.CTMX
Morgan Stanley 24th Annual Global Healthcare Conference - Varseta-M and CX-801 advance in clinical trials, addressing major unmet needs in oncology.CTMX
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 saw pipeline progress, Regeneron expansion, and $330.3M cash with runway into 2028.CTMX
Q2 2026 - Varseta-M delivers unprecedented efficacy in late-line CRC, with broad expansion and strong funding.CTMX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing.CTMX
Jefferies Global Healthcare Conference 2026 - CX-2051 shows promising efficacy in late-line CRC, with pivotal data and expansion plans ahead.CTMX
Cantor Global Healthcare Conference 2025
)
)
)
)
)
)
)
)